Cellceutix Provides Update on Phase 2b Clinical Trial for Acute Bacterial Skin and Skin Structure Infections

Cellceutix Corporation (OTCMKTS:CTIX) reported that through March 7, a total of 14 patients have been treated in the Company’s Phase 2b clinical (7% of the 200 patients to be treated) study, which aims to evaluate the safety and efficacy of Brilacidin as a novel antibiotic drug candidate for the treatment of Acute Bacterial Skin and Skin Structure Infections.

As quoted in the press release:

Patients are receiving one of three different dosing regimens of Brilacidin (one of two single-dose regimens or one 3-day regimen) or a 7-day regimen of daptomycin. Cellceutix is pleased with the initial enrollment pace and believes that it will continue to escalate as the trial moves forward.

Click here to read the Cellceutix Corporation (OTCMKTS:CTIX) press release